ThalidomideRaresideeffectsPharmacovigilancePublictrustHumorsAntifreezeGeorgeWashingtonDecisionfatigueDataheterogeneityDrug-inducedliver injuryCIOMSRadithorInnovationRealworlddataSafetyHumanoversightPenicillinPharmBERTPharmaceuticalsPatientsafetyFinancialburdenBiasAskFDALabelPatientforumsEvidencebasedAIintegrationPrivacypolicyLongtermsafetyOxycontinAddictionBlackboxmodelsEfficiencyFairnessDemographicsDrugregulationPalantirPhase1SafetydatabasesPatientrecruitmentClinicaltrialsHIPAAInterpretabilityOuraRingDisproportionalityanalysisOverdoseWearabletechTransparencyTragediesSulfanilamideBreakthroughsConfidentialityCybersecurityNaturallanguageprocessingEMAIBMWatsonCaseprocessingInnovationvs cautionDuplicatedetectionIdentitytheftFutureimplicationsRisk-basedapproachEfficacyDataprivacyOpioidcrisisTraditionAccidentaldiscoveryBloodlettingTrustFDAUnsaferecommendationsResponsibilityMedicalcodingBalancedpartnershipSignaldetectionToxiccompoundRadioactivehazardGlobalharmonisationLifecyclegovernanceThalidomideRaresideeffectsPharmacovigilancePublictrustHumorsAntifreezeGeorgeWashingtonDecisionfatigueDataheterogeneityDrug-inducedliver injuryCIOMSRadithorInnovationRealworlddataSafetyHumanoversightPenicillinPharmBERTPharmaceuticalsPatientsafetyFinancialburdenBiasAskFDALabelPatientforumsEvidencebasedAIintegrationPrivacypolicyLongtermsafetyOxycontinAddictionBlackboxmodelsEfficiencyFairnessDemographicsDrugregulationPalantirPhase1SafetydatabasesPatientrecruitmentClinicaltrialsHIPAAInterpretabilityOuraRingDisproportionalityanalysisOverdoseWearabletechTransparencyTragediesSulfanilamideBreakthroughsConfidentialityCybersecurityNaturallanguageprocessingEMAIBMWatsonCaseprocessingInnovationvs cautionDuplicatedetectionIdentitytheftFutureimplicationsRisk-basedapproachEfficacyDataprivacyOpioidcrisisTraditionAccidentaldiscoveryBloodlettingTrustFDAUnsaferecommendationsResponsibilityMedicalcodingBalancedpartnershipSignaldetectionToxiccompoundRadioactivehazardGlobalharmonisationLifecyclegovernance

BIEN4110 - Call List

(Print) Use this randomly generated list as your call list when playing the game. There is no need to say the BINGO column name. Place some kind of mark (like an X, a checkmark, a dot, tally mark, etc) on each cell as you announce it, to keep track. You can also cut out each item, place them in a bag and pull words from the bag.


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
  1. Thalidomide
  2. Rare side effects
  3. Pharmacovigilance
  4. Public trust
  5. Humors
  6. Antifreeze
  7. George Washington
  8. Decision fatigue
  9. Data heterogeneity
  10. Drug-induced liver injury
  11. CIOMS
  12. Radithor
  13. Innovation
  14. Realworld data
  15. Safety
  16. Human oversight
  17. Penicillin
  18. PharmBERT
  19. Pharmaceuticals
  20. Patient safety
  21. Financial burden
  22. Bias
  23. AskFDALabel
  24. Patient forums
  25. Evidencebased
  26. AI integration
  27. Privacy policy
  28. Longterm safety
  29. Oxycontin
  30. Addiction
  31. Black box models
  32. Efficiency
  33. Fairness
  34. Demographics
  35. Drug regulation
  36. Palantir
  37. Phase 1
  38. Safety databases
  39. Patient recruitment
  40. Clinical trials
  41. HIPAA
  42. Interpretability
  43. Oura Ring
  44. Disproportionality analysis
  45. Overdose
  46. Wearable tech
  47. Transparency
  48. Tragedies
  49. Sulfanilamide
  50. Breakthroughs
  51. Confidentiality
  52. Cybersecurity
  53. Natural language processing
  54. EMA
  55. IBM Watson
  56. Case processing
  57. Innovation vs caution
  58. Duplicate detection
  59. Identity theft
  60. Future implications
  61. Risk-based approach
  62. Efficacy
  63. Data privacy
  64. Opioid crisis
  65. Tradition
  66. Accidental discovery
  67. Bloodletting
  68. Trust
  69. FDA
  70. Unsafe recommendations
  71. Responsibility
  72. Medical coding
  73. Balanced partnership
  74. Signal detection
  75. Toxic compound
  76. Radioactive hazard
  77. Global harmonisation
  78. Lifecycle governance